It has experienced a hiccup, but the company is still on the right path. That’s the opinion of Roth MKM analyst Bill Kirk on ...

In a report released on November 8, Lisa Lewandowski from Bank of America Securities reiterated a Sell rating on Canopy Growth (CGC – Research Report), with a price target of C$ ... dampen investor ...

Canopy Growth's revenue and EBITDA have been disappointing, and analysts' projections for FY25 and FY26 remain weak. Read why ...

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors. The post Should You Buy ...

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

The company saw a huge decline in Canadian adult-use cannabis, with revenues down 24% at C$18.4 million from that category, offsetting the 16% gain from Canadian medical cannabis which reached C$18.7 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) will report the second quarter of fiscal year 2025 ended Sept. 30, before ...

Analysts estimate that Canopy Growth will report an earnings per share (EPS) of $-0.32. The announcement from Canopy Growth is eagerly anticipated, with investors seeking news of surpassing estimates ...

Canopy saw a significant decline in Canadian adult-use cannabis, where revenue fell 24% to C$18.4 million. This offset the 16% gain from Canadian medical cannabis which reached C$18.7 million, and ...